Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V + Bifidobacterium longum BB536
- Development stage
- Phase 4
- Lead developer
- Morinaga Milk Industry
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
A probiotic mixture consisting of three specific strains: *Bifidobacterium infantis* M-63, *Bifidobacterium breve* M-16V, and *Bifidobacterium longum* BB536. Developed and evaluated by researchers at Federico II University, this combination is intended to treat abdominal pain-associated functional gastrointestinal disorders (FGIDs) in children, specifically irritable bowel syndrome (IBS) and functional dyspepsia (FD). The mechanism involves modulating the gut microbiota and potentially influencing the gut-brain axis to reduce pain frequency and intensity. Clinical trials have shown significant improvement in IBS symptoms, though results for FD were less conclusive.
- Other names
- Mixture of three BifidobacteriaBifidobacteria mixture
Beyond the preview
Go deeper on Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V + Bifidobacterium longum BB536.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis M-63 + Bifidobacterium breve M-16V + Bifidobacterium longum BB536.